Globus Medical

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Philosophy, Spine, Globus Medical, Telephone, ID, Surgeon, NuVasive, GAAP, Webcast, Patient, EPS, Globus, Pharmaceutical industry

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
  • U.S. net sales for the fourth quarter of 2023 increased by 111.1% compared to the fourth quarter of 2022. International net sales increased by 200.9% over the fourth quarter of 2023 on an as-reported basis, and an increase of 200.8% on a constant currency basis.
  • Diluted EPS for the fourth quarter was $0.11, compared to $0.49 for the fourth quarter of 2022.
  • Globus Medical will hold a teleconference to discuss its 2023 fourth quarter and full year results with the investment community at 4:30 p.m. Eastern Time today.

Dror Paley, MD to Lead World's First Surgery with the PRECICE® Max System at Paley Orthopedic & Spine Institute

Retrieved on: 
Tuesday, February 20, 2024
PALM, Reconstruction, Weight-bearing, Globus Medical, Tibia, FDA, Femur, History, Health, NSO, Patient, Ageing, MAX, Birth control

WEST PALM BEACH, Fla,, Feb. 20, 2024 /PRNewswire-PRWeb/ -- Dr. Dror Paley, a globally renowned orthopedic surgeon and the Founder & CEO of the Paley Orthopedic & Spine Institute, is set to make medical history as he performs the first surgery in the world utilizing the PRECICE® Max System, developed by NuVasive Specialized Orthopedics™ (NSO), now a part of Globus Medical. This groundbreaking surgery marks a significant step forward in orthopedic innovation, emphasizing Dr. Paley's steadfast dedication to advancing the field and improving patient care. Furthermore, his selection as the inaugural surgeon further solidifies his reputation as the foremost authority in Limb Lengthening Deformity & Reconstruction Surgery worldwide.

Key Points: 
  • This groundbreaking surgery marks a significant step forward in orthopedic innovation, emphasizing Dr. Paley's steadfast dedication to advancing the field and improving patient care.
  • Furthermore, his selection as the inaugural surgeon further solidifies his reputation as the foremost authority in Limb Lengthening Deformity & Reconstruction Surgery worldwide.
  • Reflecting on the significance of this advancement, Dr. Paley stated, "I'm thrilled about the new Precice Max nail that I've contributed to developing.
  • As a global leader in orthopedic surgery, Dr. Paley's dedication to innovation and patient well-being shapes the future of orthopedic medicine.

Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Retrieved on: 
Tuesday, February 13, 2024
Globus Medical, ID, Webcast, Telephone

A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .

Key Points: 
  • A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .
  • Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time.
  • Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts .
  • The audio archive will be available after the call on the Investor page of the Globus Medical website.

Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Monday, February 5, 2024
NuVasive, Growth, Pfeil, Globus, CFO, Globus Medical, Management

AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO).

Key Points: 
  • AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO).
  • Having served as the Company’s CFO since August 2019, in this expanded role, Pfeil will help further drive the Company's strategic roadmap through business and operational planning as well as financial performance management.
  • "With a track record of over 20 years of high-performance industry experience, including the past four years with Globus, Keith has demonstrated operational and financial leadership and a deep passion for our business," said Dan Scavilla, president and chief executive officer of Globus Medical, to whom Pfeil will continue reporting.
  • The Company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

Retrieved on: 
Wednesday, January 10, 2024
Seed, Patient, Health, CFO, Spine, Enabling, Globus Medical, Globus, NuVasive

AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.
  • The company anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022 on an as-reported basis.
  • “Excluding the impacts of the September 1, 2023 merger with NuVasive, Inc., legacy Globus fourth quarter revenue was approximately $302.9 million, an increase of 10.4 percent over the prior year fourth quarter.
  • The company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Retrieved on: 
Wednesday, January 3, 2024
NSPR, NuVasive, TEL, Stroke, Integra, IDE, Globus Medical, Integra LifeSciences, Orthopedic surgery, Growth, Rutgers University, Patient, Compensated emancipation, Stenosis, Employment, Syracuse University, NSO, EPS, Senior

TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
  • Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.
  • Before that, he served as Vice President of Global Commercial Strategy at Smith+Nephew, and, prior to that, in various roles of increasing responsibility at Integra LifeSciences, culminating with Senior Vice President and General Manager - Extremity Orthopedics.
  • In connection with the appointment of Mr. Ligotti as Executive Vice President and General Manager of North America, InspireMD has granted Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of InspireMD’s common stock.

Globus Medical Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
DSM-IV codes, NYSE, Globus Medical, EBITDA, Telephone, GAAP, Acquisition, NuVasive, EPS, ID, Surgeon, Webcast, Culture, Patient, Pharmaceutical industry, Video game

AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023.
  • The merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date.
  • Non-GAAP adjusted EBITDA was $112.9 million, or 29.4% of net sales
    Stand-alone Globus Medical net sales were $281.2 million, an increase of 10.7%
    “The third quarter of 2023 was a defining moment for Globus Medical, as we completed our planned merger with NuVasive to create the most innovative company in the spine industry.
  • Globus Medical will hold a teleconference to discuss its third quarter 2023 results with the investment community at 4:30 p.m. Eastern Time today.

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

Retrieved on: 
Tuesday, October 24, 2023
Globus Medical, Telephone, ID, NYSE, Webcast

A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .

Key Points: 
  • A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .
  • Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time.
  • Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts .
  • The audio archive will be available after the call on the Investor page of the Globus Medical website.

Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Simplification, VAS, North American Spine Society, NYSE, Globus Medical, ACDF, NASS, Spine, Visual analogue scale, Contraindication, Annual general meeting, Overalls, NDI, Motion, Birth control

AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, presented five-year outcomes from the NuVasive Simplify Cervical Disc study at the North American Spine Society (NASS) 38th Annual Meeting.

Key Points: 
  • AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, presented five-year outcomes from the NuVasive Simplify Cervical Disc study at the North American Spine Society (NASS) 38th Annual Meeting.
  • The study demonstrates positive, long-term clinical outcomes, a high rate of overall composite success at 60 months, and statistical superiority to anterior cervical discectomy fusion (ACDF) procedural outcomes.
  • “Having clinically backed, long-term data for the Simplify Cervical Disc validates the promising clinical data we saw Simplify having at the two-year mark,” said Kyle Malone, senior vice president, Scientific Affairs of Globus Medical.
  • Dr. Pierce Nunley of the Spine Institute of Louisiana expressed his enthusiasm about the durability of the positive outcomes observed at 24 months.

ATEC Enhances Board with Renowned Spine Prowess

Retrieved on: 
Tuesday, October 17, 2023
Health, Biometrics, Health Technology, Other Health, General Health, Pharmaceutical, Biotechnology, Special, Organization, Heart, Spine, Keith, Marketing, Friends, Emerging technologies, ATEC, Globus Medical, Management

"I want to address one matter, clearly and directly," added Miles. "We are aware of the recent negative commentary directed at Keith by his former employer. Years ago, I too was the target of a very public assault. During that time, I was blessed to be supported by friends who knew me best, and who rejected the accusations of strangers. I have known Keith for 30 years -- I know his imperfections, but I also know his heart. He is beloved by many in our industry and his impact on spine care over the years is undeniable. Keith has made it clear he is ready to devote his considerable energy to making ATEC better, and I am thrilled to have him join our effort."

Key Points: 
  • The Company also announced that Keith Valentine, former Chief Executive Officer of Orthofix, has been appointed Special Advisor to the Board.
  • With over 20 years of experience in spine, Demski served most recently on the Globus Medical Board of Directors from 2003 to 2022.
  • "While conglomerateurs and capitulants continue to form awkward alliances, ATEC has emerged as the most clinically focused spine-only company.
  • Our success is due to our relentless pursuit to improve spine care, and certainty that people and know-how will always differentiate ATEC.